Current Progress on The Neuroprotective Effects of Isothiocyanates in The Treatment for Experimental Parkinson's Disease / 中国药学杂志

ABSTRACT

Parkinson's disease (PD) is recognized as the second most common neurodegenerative disorder and is characterized by a slow and progressive degeneration of dopaminergic neurons in the substantia nigra. Despite intensive research, the mechanisms involved in neuronal loss are not completely understood yet; however, misfolded proteins, oxidative stress, excitotoxicity and inflammation play a pivotal role in the progression of the pathology. To date, no efficient therapy that arrest or slow down PD is available. Isothiocyanates (ITCs) have already shown interesting properties in detoxification, inflammation, apoptosis and cell cycle regulation through the induction of phase and phase Ⅱ enzyme. Moreover, ITCs may be able to modulate several key points in oxidative and inflammatory evolution. In this review, we describe ITCs as pleiotropic compounds capable of preventing and modulating the evolution of PD. In particular, we summarized the neuroprotective effects of sulforaphane (SFN), erucin (ER), phenethyl isothiocyanate (PEITC) and 6-(methylsulfinyl) hexyl isothiocyanate (6-MSITC) in the treatment for experimental PD.